All News
Filter News
Found 2,649 articles
-
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
1/22/2024
Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced four-year follow-up results from the CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) vs. sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC).
-
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
1/22/2024
Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28% in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) vs. sunitinib after eight years, regardless of International Metastatic RCC Database Consortium (IMDC) risk group.
-
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
1/22/2024
EMD Serono today announced new real-world data that continue to reinforce the JAVELIN Bladder regimen of first-line platinum-based chemotherapy followed by BAVENCIO® (avelumab) maintenance as a standard of care for eligible patients with locally advanced or metastatic urothelial carcinoma (UC) who do not progress on first-line chemotherapy.
-
Gilead Provides Update on Phase 3 EVOKE-01 Study
1/22/2024
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
-
GeneCentric Therapeutics Announces Upcoming Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium and Precision Medicine World Conference
1/22/2024
GeneCentric Therapeutics today announced upcoming presentations at the Precision Medicine World Conference (PMWC) in Santa Clara, California from January 24-26 and the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which will be held January 25-27 in San Francisco, California.
-
Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient mCRC in CheckMate -8HW Trial
1/20/2024
Bristol Myers Squibb announced results from the Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy compared to investigator’s choice of chemotherapy as a first-line treatment for patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.
-
U.S. Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
1/19/2024
Johnson & Johnson announced that the U.S. Food and Drug Administration approved a supplemental New Drug Application for BALVERSA® for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible fibroblast growth factor receptor 3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.
-
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
1/18/2024
Shanghai Junshi Biosciences Co., Ltd announced the publication of results from the prespecified interim analysis for event-free survival in patients with stage III non-Small Cell Lung Cancer of NEOTORCH in theJournal of the American Medical Association.
-
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
1/17/2024
UroGen Pharma Ltd. today announced a licensing agreement with medac GmbH to develop a next-generation novel mitomycin-based formulation for urothelial cancers.
-
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
1/17/2024
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California.
-
Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
1/16/2024
Ferring Pharmaceuticals announced that ADSTILADRIN® is now fully available across the U.S. for healthcare providers to prescribe for their adult patients with high-risk Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.
-
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
1/15/2024
Theralase Technologies Inc. is providing an update regarding its Phase II Non-Muscle Invasive Bladder Cancer (" NMIBC ") clinical study (" Study II ").
-
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
1/12/2024
Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer.
-
UroGen Pharma to Participate in the B. Riley Healthcare Conference
1/11/2024
UroGen Pharma Ltd. today announced that Liz Barrett, President and CEO, will participate in a fireside chat at the upcoming B. Riley Virtual Healthcare Conference on January 18th.
-
Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
1/10/2024
Shanghai Junshi Biosciences Co., Ltd announced the publication of results from TORCHLIGHT, a randomized, double-blind, placebo-controlled phase 3 study comparing the efficacy and safety of toripalimab versus placebo, in combination with nab-paclitaxel for patients with newly diagnosed metastatic or recurrent locally advanced triple-negative breast cancer in Nature Medicine.
-
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
1/8/2024
Janux Therapeutics, Inc. today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer.
-
Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
1/5/2024
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors.
-
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
1/4/2024
Immutep Limited today announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial.
-
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
1/2/2024
Shanghai Junshi Biosciences Co., Ltd announced that the supplemental new drug application (the “sNDA”) for toripalimab (trade name: TUOYI®, product code: JS001) in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (“NSCLC”) has been approved by the National Medical Products Administration.
-
Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
12/22/2023
Tyra Biosciences, Inc. today announced that it has initiated the SURF201 Phase 1 study of TYRA-200 and provided positive updates on its oral FGFR3-selective inhibitor, TYRA-300.